Sign In
Buy SEMHF
Siemens Healthineers Ag Earnings Calls
| Release date | May 07, 2026 |
| EPS estimate | $0.583 |
| EPS actual | $0.612 |
| EPS Surprise | 4.97% |
| Revenue estimate | 6.853B |
| Revenue actual | 6.564B |
| Revenue Surprise | -4.22% |
| Release date | Feb 05, 2026 |
| EPS estimate | $0.524 |
| EPS actual | $0.576 |
| EPS Surprise | 9.92% |
| Revenue estimate | 6.22B |
| Revenue actual | 6.345B |
| Revenue Surprise | 2.01% |
| Release date | Nov 05, 2025 |
| EPS estimate | $0.81 |
| EPS actual | $0.617 |
| EPS Surprise | -23.54% |
| Revenue estimate | 6.058B |
| Revenue actual | 10.376B |
| Revenue Surprise | 71.28% |
| Release date | Jul 30, 2025 |
| EPS estimate | $0.625 |
| EPS actual | $0.577 |
| EPS Surprise | -7.68% |
| Revenue estimate | 7.63B |
| Revenue actual | 6.667B |
| Revenue Surprise | -12.62% |
Last 4 Quarters for Siemens Healthineers Ag
Below you can see how SEMHF performed 4 days prior and 4 days after releasing the earnings report. Also, you can see the pre-estimates and the actual earnings. This information can give you a slight idea of what you might expect for the next quarter's release.
| Release date | Jul 30, 2025 |
| Price on release | $56.60 |
| EPS estimate | $0.625 |
| EPS actual | $0.577 |
| EPS surprise | -7.68% |
| Date | Price |
|---|---|
| Jul 24, 2025 | $56.90 |
| Jul 25, 2025 | $54.72 |
| Jul 28, 2025 | $55.60 |
| Jul 29, 2025 | $56.36 |
| Jul 30, 2025 | $56.60 |
| Jul 31, 2025 | $55.70 |
| Aug 01, 2025 | $53.85 |
| Aug 04, 2025 | $54.50 |
| Aug 05, 2025 | $54.89 |
| 4 days before | -0.527% |
| 4 days after | -3.02% |
| On release day | -1.59% |
| Change in period | -3.53% |
| Release date | Nov 05, 2025 |
| Price on release | $52.60 |
| EPS estimate | $0.81 |
| EPS actual | $0.617 |
| EPS surprise | -23.54% |
| Date | Price |
|---|---|
| Oct 30, 2025 | $57.75 |
| Oct 31, 2025 | $54.45 |
| Nov 03, 2025 | $56.22 |
| Nov 04, 2025 | $56.22 |
| Nov 05, 2025 | $52.60 |
| Nov 06, 2025 | $53.18 |
| Nov 07, 2025 | $52.58 |
| Nov 10, 2025 | $50.00 |
| Nov 11, 2025 | $49.48 |
| 4 days before | -8.92% |
| 4 days after | -5.93% |
| On release day | 1.10% |
| Change in period | -14.32% |
| Release date | Feb 05, 2026 |
| Price on release | $50.34 |
| EPS estimate | $0.524 |
| EPS actual | $0.576 |
| EPS surprise | 9.92% |
| Date | Price |
|---|---|
| Jan 30, 2026 | $52.06 |
| Feb 02, 2026 | $51.59 |
| Feb 03, 2026 | $51.40 |
| Feb 04, 2026 | $51.27 |
| Feb 05, 2026 | $50.34 |
| Feb 06, 2026 | $50.40 |
| Feb 09, 2026 | $48.27 |
| Feb 10, 2026 | $48.58 |
| Feb 11, 2026 | $48.00 |
| 4 days before | -3.30% |
| 4 days after | -4.65% |
| On release day | 0.119% |
| Change in period | -7.79% |
| Release date | May 07, 2026 |
| Price on release | $40.20 |
| EPS estimate | $0.583 |
| EPS actual | $0.612 |
| EPS surprise | 4.97% |
| Date | Price |
|---|---|
| May 01, 2026 | $40.72 |
| May 04, 2026 | $39.86 |
| May 05, 2026 | $41.12 |
| May 06, 2026 | $41.88 |
| May 07, 2026 | $40.20 |
| May 08, 2026 | $39.95 |
| May 11, 2026 | $40.56 |
| May 12, 2026 | $40.62 |
| May 13, 2026 | $40.46 |
| 4 days before | -1.28% |
| 4 days after | 0.659% |
| On release day | -0.603% |
| Change in period | -0.626% |
Siemens Healthineers Ag Earnings Call Transcript Summary of Q1 2026
Siemens Healthineers started fiscal 2026 with solid performance in its synergistic core (Imaging and Precision Therapy) that offset significant tariff and FX headwinds; the company confirmed its full-year revenue and adjusted EPS outlook. Imaging and Precision Therapy grew ~6% combined, delivered operational margin expansion, and benefited from strong product momentum (Photon Counting CT, PETNET, Varian). Diagnostics declined ~3% primarily due to unforeseen, material market disruptions in China (volume-based procurement and reimbursement reductions) which hit both revenue and profitability; Diagnostics' China exposure is now a smaller share (~7–8%) but poses near-term headwinds and could require adjustments to segment assumptions. Management is progressing preparations for deconsolidation from Siemens AG (including refinancing) and received an investment-grade rating from Moody's. Near-term: Q2 group growth is expected below the company’s 5–6% range, with Diagnostics in China likely to remain weak; tariffs and FX will continue to be headwinds in H1. Management emphasized commitment to long-term strategy (Elevating Health Globally), value partnerships, and midterm margin improvement excluding temporary tariff impacts.
